CVS Health Corporation (NYSE:CVS - Get Free Report) announced a quarterly dividend on Monday, July 7th, RTT News reports. Investors of record on Tuesday, July 22nd will be paid a dividend of 0.665 per share by the pharmacy operator on Friday, August 1st. This represents a $2.66 annualized dividend and a yield of 3.99%.
CVS Health has a payout ratio of 37.7% meaning its dividend is sufficiently covered by earnings. Equities analysts expect CVS Health to earn $6.77 per share next year, which means the company should continue to be able to cover its $2.66 annual dividend with an expected future payout ratio of 39.3%.
CVS Health Stock Performance
Shares of NYSE CVS traded down $0.75 during trading on Monday, reaching $66.68. 6,418,905 shares of the company traded hands, compared to its average volume of 10,833,454. The firm has a 50 day simple moving average of $65.11 and a 200-day simple moving average of $61.71. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $84.35 billion, a PE ratio of 15.91, a P/E/G ratio of 0.97 and a beta of 0.57. CVS Health has a 52-week low of $43.56 and a 52-week high of $72.51.
CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter last year, the firm posted $1.31 EPS. The business's quarterly revenue was up 7.0% compared to the same quarter last year. Equities research analysts anticipate that CVS Health will post 5.89 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of research firms have commented on CVS. Morgan Stanley restated an "overweight" rating on shares of CVS Health in a research note on Tuesday, April 15th. Barclays set a $79.00 target price on shares of CVS Health and gave the stock an "overweight" rating in a research note on Monday, June 2nd. Robert W. Baird raised their target price on shares of CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Jefferies Financial Group lifted their price objective on shares of CVS Health from $74.00 to $80.00 and gave the company a "buy" rating in a research report on Monday, June 30th. Finally, Piper Sandler lifted their price objective on shares of CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research report on Friday, March 21st. Two investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $75.06.
Get Our Latest Report on CVS Health
Insider Buying and Selling
In other news, Director Guy P. Sansone acquired 1,570 shares of the company's stock in a transaction on Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the purchase, the director directly owned 12,007 shares of the company's stock, valued at $764,845.90. This represents a 15.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.22% of the stock is owned by insiders.
CVS Health Company Profile
(
Get Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Recommended Stories

Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.